Context Therapeutics’ (CNTX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Context Therapeutics (NASDAQ:CNTX) in a report released on Friday morning,Benzinga reports. HC Wainwright currently has a $5.00 price target on the stock. HC Wainwright also issued estimates for Context Therapeutics’ Q3 2025 earnings at ($0.05) EPS and Q4 2025 earnings at ($0.05) EPS.

A number of other research firms also recently issued reports on CNTX. D. Boral Capital restated a “buy” rating and issued a $9.00 target price on shares of Context Therapeutics in a research report on Wednesday, January 15th. Citizens Jmp upgraded shares of Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th. Finally, JMP Securities initiated coverage on shares of Context Therapeutics in a research report on Wednesday, January 8th. They set an “outperform” rating and a $4.00 price target on the stock. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $6.17.

Context Therapeutics Stock Performance

Shares of CNTX stock opened at $0.77 on Friday. The firm’s 50 day moving average price is $0.85 and its two-hundred day moving average price is $1.43. The stock has a market cap of $57.88 million, a PE ratio of -0.85 and a beta of 2.06. Context Therapeutics has a 52-week low of $0.64 and a 52-week high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01. As a group, sell-side analysts predict that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Institutional Trading of Context Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CNTX. State Street Corp increased its position in shares of Context Therapeutics by 21.5% during the third quarter. State Street Corp now owns 111,907 shares of the company’s stock valued at $219,000 after acquiring an additional 19,800 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in Context Therapeutics in the 3rd quarter worth $89,000. Franklin Resources Inc. bought a new position in Context Therapeutics in the 3rd quarter worth $3,689,000. Clear Harbor Asset Management LLC boosted its holdings in Context Therapeutics by 60.6% in the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock worth $61,000 after buying an additional 21,804 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Context Therapeutics by 9.2% during the 4th quarter. Geode Capital Management LLC now owns 628,729 shares of the company’s stock valued at $661,000 after purchasing an additional 52,830 shares during the last quarter. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.